The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries
- 15 October 2013
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 31 (11) , 1063-1082
Abstract
Background Almost 300 million people suffer from asthma, yet many in low- and middle-income countries have difficulty accessing essential asthma medicines. Availability, price and affordability of medicines are likely to affect access. Very few studies have included asthma medicines, particularly inhaled corticosteroids, in these countries. Reflections about international reference prices (IRPs) are generally absent from pricing studies, yet some IRPs may be masking the extent of access problems. Objectives Our objective was to determine the availability, pricing and affordability of beclometasone, budesonide and salbutamol, the three asthma medicines on the World Health Organization’s Model List of Essential Medicines (EML) in selected low- and middle-income countries and to reflect on the appropriateness of using IRPs. Methods A cross-sectional pricing survey was conducted in 52 countries. Data were collected on country demographics including national currency, $US exchange rate and daily wage of the lowest-paid unskilled government worker. Pricing and availability data were collected for salbutamol, beclometasone and budesonide in two private retail pharmacies, the national procurement centre and a main public hospital. Results Availability was particularly poor for corticosteroids, and worse in national procurement centres and main hospitals. The surveyed strength of beclometasone was only on the EML of ten countries. Considerable variability was found in pricing and affordability across countries. Procurement systems appeared largely inefficient when Asthma Drug Facility prices were applied as references. Some countries appear to be subsidising asthma medicines, making them free or less expensive for patients, while other countries are applying very high margins, which can significantly increase the price for patients unless a reimbursement system exists. Conclusions Findings raise important policy concerns. Availability of inhaled corticosteroids is poor; many EMLs are not updated; IRPs can be misleading; health systems and patients are paying more than necessary for asthma medicines, which are unaffordable for many patients in many countries.Keywords
This publication has 13 references indexed in Scilit:
- Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing WorldPLOS Medicine, 2010
- Economic burden of asthma: a systematic reviewBMC Pulmonary Medicine, 2009
- Availability, price and affordability of asthma medicines in five Indian states.2009
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countriesBulletin of the World Health Organization, 2007
- Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in MalaysiaPLOS Medicine, 2007
- Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveysThe Lancet, 2006
- Cost of asthma in the Asia-Pacific regionEuropean Respiratory Review, 2006
- Increase in diagnosed asthma but not in symptoms in the European Community Respiratory Health SurveyThorax, 2004
- Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveysJournal of Allergy and Clinical Immunology, 2004